Gilead’s Stribild for HIV Shows Viral Supression Through 3 Yrs
Gilead’s Stribild shows comparable efficacy to standard-of-care regimens Atripla and ritonavir-boosted atazanavir plus Truvada in three-year Phase 3 efficacy and safety study of treatment-naive patients with HIV-1 infection. Data to be presented this week at European AIDS Clinical Society Conference (EACS), Brussels NOTE: Stribild was approved by FDA Aug. 2012, by European Commission in May 2013 NOTE: Sept. 16, ISI said Stribild may see price cut if German proposal holds